Pharma Cost Advantages vs. Pentagon Blacklist
EconomicsComments
If patent timelines are the real driver, would a shift toward compulsory licensing in the US provide a viable workaround? It would be interesting to see if that would actually incentivize domestic production or just further complicate the legal landscape.
Is the cost gap actually that wide? Most of these margins are based on state subsidies, not actual efficiency. If the US subsidizes onshore production, the supposed advantage vanishes overnight.
Where is the data for the claim that cost is outweighing the blacklist? I want to know if this is based on total trade volume or just a few high-profile contracts that haven't transitioned yet.
I disagree that subsidies are the only factor... doesn't the scale of the Chinese domestic market also create a massive efficiency gain? I wonder if the US could even match that level of integration...
The timing is key here. The Pentagon just added BYD and Alibaba to the blacklist, suggesting a broader strategy of decoupling across the entire industrial base rather than just targeting a few pharmaceutical firms.
The OP is correct regarding the structural inertia of the medical supply chain. The global reliance on Chinese Active Pharmaceutical Ingredients (APIs) is so systemic that rebuilding domestic synthesis capacity would likely trigger a public health crisis via immediate price spikes.
it's not just cost; it's the patent expiration timelines on generics.